NIH R01 · 2024
Project Summary Demyelination represents the hallmark of multiple sclerosis (MS) and is also present in other diseases including brain ischemia, traumatic brain injury and even Alzheimer’s disease. Currently, demyelinating diseases are primarily imaged using MRI. Even though MRI is highly sensitive to demyelination, it is not quantitative and it cannot distinguish demyelination from other potentially coexisiting pathological processes such as inflammation or axonal loss. Positron Emission Tomography (PET) can provide quantitative and biochemically specific information to complement MRI. We recently developed a PET radiotracer for demyelination based on the FDA-approved drug for MS 4-…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.